首页 > 市场调查报告书 > 製药

骨疾病

市场调查报告书

商品编码

1569496

骨质疏鬆症药物市场规模、份额和成长分析：按药物类别、类型、分销管道和地区划分 - 产业预测，2024-2031 年

Osteoporosis Drugs Market Size, Share, Growth Analysis, By Drug Class (Branded, Generic), By Type (Bisphosphonates, Parathyroid Hormone), By Distribution Channel (Retail Pharmacy, Online Pharmacy), By Region - Industry Forecast 2024-2031

出版日期: 2024年10月11日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球骨质疏鬆药物市场规模为71亿美元，从2023年的73.4亿美元增加至2031年的95.9亿美元，复合年增长率预计为3.40%。

全球骨质疏鬆症药物市场正在经历强劲成长，主要是由于骨质疏鬆症盛行率不断增加，特别是在人口老化中。这种慢性疾病的特征是骨骼密度下降和骨折风险增加，使人们迅速认识到早期诊断和及时治疗方案的重要性。除了人们所认识的提升之外，骨质疏鬆症治疗方法（包括创新治疗方法和标靶药物传递系统）开发的重大进展也进一步支持了市场的扩张。然而，与骨质疏鬆症药物相关的挑战，例如高成本和长期使用的潜在副作用，正在阻碍市场扩张。儘管存在这些障碍，对有效和安全的骨质疏鬆症药物不断增长的需求预计将在未来几年保持市场势头。具体而言，美国骨质疏鬆症药物市场预计在下一个预测期内将保持稳定的年复合成长率（CAGR），这将导致解决这一普遍健康问题的治疗方法，这反映了我们对骨质疏鬆症的持续承诺。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Amgen Inc.（US）
Eli Lilly and Company（US）
Merck & Co., Inc.（US）
Novartis International AG（Switzerland）
Pfizer Inc.（US）
GlaxoSmithKline plc（UK）
Radius Health, Inc.（US）
UCB SA（Belgium）
Teva Pharmaceutical Industries Ltd.（Israel）
Roche Holding AG（Switzerland）
Bristol-Myers Squibb Company（US）
Sanofi SA（France）
AbbVie Inc.（US）
AstraZeneca PLC（UK）
Hologic, Inc.（US）
Lundbeck A/S（Denmark）
Eisai Co., Ltd.（Japan）
Ferring Pharmaceuticals（Switzerland）
Sandoz International GmbH（Switzerland）
Servier Laboratories（France）
Bayer AG（Germany）
Grunenthal GmbH（Germany）

简介目录

Product Code: SQMIG35I2282

Global Osteoporosis Drugs Market size was valued at USD 7.1 billion in 2022 and is poised to grow from USD 7.34 billion in 2023 to USD 9.59 billion by 2031, growing at a CAGR of 3.40% during the forecast period (2024-2031).

The global osteoporosis drugs market is witnessing robust growth, primarily driven by the increasing prevalence of osteoporosis, particularly among the aging population. As this chronic condition is characterized by diminished bone density and heightened risk of fractures, there has been a surge in awareness regarding the importance of early diagnosis and timely treatment options. This heightened awareness, coupled with significant advancements in the development of osteoporosis treatments-such as innovative therapies and targeted drug delivery systems-has further propelled the market's expansion. Nevertheless, challenges such as the high costs associated with osteoporosis medications and potential side effects from long-term usage pose hurdles to market progress. Despite these obstacles, the escalating demand for both effective and safe osteoporosis treatments is anticipated to sustain market momentum in the coming years. Specifically, the U.S. osteoporosis drugs market is expected to maintain a steady compound annual growth rate (CAGR) during the next forecast period, reflecting the ongoing commitment to addressing this prevalent health concern and improving patient outcomes through improved therapies and increased accessibility.

Top-down and bottom-up approaches were used to estimate and validate the size of the global osteoporosis drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

global osteoporosis drugs Market Segmental Analysis

Global Osteoporosis Drugs Market is segmented by Drug Class, Type, Distribution Channel, and region. Based on Drug Class, the market is segmented into Branded, and Generic. Based on Type, the market is segmented into Bisphosphonates, Parathyroid Hormone, Calcitonin, Selective Estrogen Inhibitor Modulator, Rank Ligand Inhibitor, and Others. Based on Distribution Channel, the market is segmented into Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the global osteoporosis drugs Market

The burgeoning aging population worldwide serves as a significant market driver for the global osteoporosis drugs market. As life expectancy rises, the incidence of osteoporosis increases, resulting in heightened demand for effective treatment solutions. This demographic shift is compounded by growing awareness of bone health, leading to more frequent diagnoses of osteoporosis and, consequently, a greater need for therapeutic options. Moreover, continuous advancements in pharmaceutical research, including the development of innovative drugs with enhanced efficacy and safety profiles, are further propelling market growth. Together, these factors create a robust environment for expanding osteoporosis treatment options globally.

Restraints in the global osteoporosis drugs Market

A significant restraint in the global osteoporosis drugs market is the high cost of treatment, which often poses a barrier to patient access and adherence. Osteoporosis management typically necessitates prolonged medication and continuous monitoring, leading to substantial financial burdens, particularly for individuals in low-income or developing areas. The exorbitant prices of branded medications, coupled with inadequate insurance coverage for osteoporosis therapies, create accessibility challenges for patients. This financial strain may deter potential users from seeking or maintaining necessary treatments, thereby restricting the overall adoption of osteoporosis drugs and stifling market growth, especially in regions with limited healthcare resources and affordability issues.

Market Trends of the global osteoporosis drugs Market

A prominent trend in the global osteoporosis drugs market is the surge in research and development aimed at innovative therapies that demonstrate enhanced efficacy and safety. With the rising global incidence of osteoporosis, pharmaceutical companies are prioritizing the creation of cutting-edge treatments that not only effectively manage the disease but also minimize fracture risks. This trend is fueled by advancements in biotechnology and novel drug delivery systems, allowing the formulation of targeted, personalized therapies. As patient-centric approaches gain traction, the market is witnessing an emergence of convenient delivery methods that align with the evolving needs of osteoporosis management, setting a transformative trajectory for the industry.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
PESTEL Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Osteoporosis Drugs Market by Drug Class

Market Overview
Branded
Generic

Osteoporosis Drugs Market by Type

Market Overview
Bisphosphonates
Parathyroid Hormone
Calcitonin
Selective Estrogen Inhibitor Modulator
Rank Ligand Inhibitor
Others

Osteoporosis Drugs Market by Distribution Channel

Market Overview
Hospitals Pharmacy
Retail Pharmacy
Online Pharmacy

Osteoporosis Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Radius Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Servier Laboratories (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grunenthal GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments